After mulling mountains of data on Endologix’s AFX2 endovascular graft, an expert panel of the FDA’s Medical Devices Advisory Committee came to an unofficial conclusion: The stent — which has had a troubling propensity to fail — may be a good option in some small niche populations, but it’s not suitable for use in broad populations.
To View This Article:
Subscribe To Device Daily Bulletin Premium
Device Daily Bulletin Premium Subscription
Upgrade to Device Daily Bulletin Premium to get all the articles in the free publication PLUS more in-depth stories on regulatory and industry developments, FDA inspection and enforcement activities and analysis of market trends. It makes sense of everything successful devicemakers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay compliant and thrive. And it’s combined with timely content from FDAnews management reports and webinars. Learn more